BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed. Prism BioLab Co. Ltd....
...protein 1 REST (NRSF) - RE1-silencing transcription factor Elizabeth S. Eaton, Staff Writer Boehringer Ingelheim GmbH Eisai Co. Ltd. PRISM BioLab Co. Ltd. protein-protein...
BioCentury | Aug 23, 2017
Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

...to start clinical testing of CCS1477 in prostate cancer in late 2017 or early 2018. Prism Pharma...
...BCIQ database, there are no companies with clinical-stage p300 inhibitors. Elizabeth S. Eaton CCS1477 PRI-724 CellCentric Ltd. Eisai Co. Ltd. Genentech Inc. PRISM BioLab Co. Ltd. Roche CREB...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

...antagonist Ph I OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Vantictumab (OMP-18R5) Frizzled homolog 7 (FZD7) Ph I Prism Pharma...
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)

...cancer and metastatic melanoma and Phase I testing to treat cancer dependent on Wnt ligands. Prism Pharma...
BioCentury | Nov 7, 2013
Distillery Therapeutics

Indication: Cancer

...tyrosine kinase inhibitor, to treat gastrointestinal stromal tumors (GISTs), acute lymphoblastic leukemia (ALL) and CML. Prism Pharma...
BioCentury | Jun 17, 2013
Clinical News

PRI-724: Phase I data

...of PRI-724 to treat liver fibrosis induced by HCV, with data expected in early 2015. Prism Pharma...
BioCentury | Jun 17, 2013
Financial News

Prism Pharma completes venture financing

Prism Pharma Co. Ltd. , Yokohama, Japan Business: Proteomics, Cancer Date completed: 6/13/13 Type: Venture financing Raised: $15 million Investors: Innovation Network Corp. of Japan (INCJ); DBJ Capital; Organization for Industry-Academia-Government Collaboration; JAFCO; Neostella Capital; Angel...
BioCentury | Jun 17, 2013
Finance

Broader spectrum

...Broader spectrum Prism Pharma Co. Ltd. plans to use the $15 million it raised in a series...
BioCentury | Jun 14, 2013
Financial News

Prism raises $15 million in series C

Prism Pharma Co. Ltd. (Yokohama, Japan) raised about $15 million in a series C round led by Innovation Network Corp. of Japan. Existing investor Development Bank of Japan also participated along with four other existing...
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...CEQ508, an oral RNAi targeting CTNNB1, is in Phase I/II testing to treat colorectal cancers. Prism Pharma...
Items per page:
1 - 10 of 13
BioCentury | Jun 11, 2020
Deals

Prism’s peptide mimetic platform finds second discovery partner

...using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed. Prism BioLab Co. Ltd....
...protein 1 REST (NRSF) - RE1-silencing transcription factor Elizabeth S. Eaton, Staff Writer Boehringer Ingelheim GmbH Eisai Co. Ltd. PRISM BioLab Co. Ltd. protein-protein...
BioCentury | Aug 23, 2017
Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

...to start clinical testing of CCS1477 in prostate cancer in late 2017 or early 2018. Prism Pharma...
...BCIQ database, there are no companies with clinical-stage p300 inhibitors. Elizabeth S. Eaton CCS1477 PRI-724 CellCentric Ltd. Eisai Co. Ltd. Genentech Inc. PRISM BioLab Co. Ltd. Roche CREB...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

...antagonist Ph I OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Vantictumab (OMP-18R5) Frizzled homolog 7 (FZD7) Ph I Prism Pharma...
BioCentury | May 12, 2016
Distillery Therapeutics

Therapeutics: β-catenin (CTNNB1); ubiquitin specific peptidase 6 (USP6)

...cancer and metastatic melanoma and Phase I testing to treat cancer dependent on Wnt ligands. Prism Pharma...
BioCentury | Nov 7, 2013
Distillery Therapeutics

Indication: Cancer

...tyrosine kinase inhibitor, to treat gastrointestinal stromal tumors (GISTs), acute lymphoblastic leukemia (ALL) and CML. Prism Pharma...
BioCentury | Jun 17, 2013
Clinical News

PRI-724: Phase I data

...of PRI-724 to treat liver fibrosis induced by HCV, with data expected in early 2015. Prism Pharma...
BioCentury | Jun 17, 2013
Financial News

Prism Pharma completes venture financing

Prism Pharma Co. Ltd. , Yokohama, Japan Business: Proteomics, Cancer Date completed: 6/13/13 Type: Venture financing Raised: $15 million Investors: Innovation Network Corp. of Japan (INCJ); DBJ Capital; Organization for Industry-Academia-Government Collaboration; JAFCO; Neostella Capital; Angel...
BioCentury | Jun 17, 2013
Finance

Broader spectrum

...Broader spectrum Prism Pharma Co. Ltd. plans to use the $15 million it raised in a series...
BioCentury | Jun 14, 2013
Financial News

Prism raises $15 million in series C

Prism Pharma Co. Ltd. (Yokohama, Japan) raised about $15 million in a series C round led by Innovation Network Corp. of Japan. Existing investor Development Bank of Japan also participated along with four other existing...
BioCentury | May 16, 2013
Distillery Therapeutics

Indication: Cancer

...CEQ508, an oral RNAi targeting CTNNB1, is in Phase I/II testing to treat colorectal cancers. Prism Pharma...
Items per page:
1 - 10 of 13